We share the information on this page with significant empathy and hope. Your depression is real. Spravato therapy, a revolutionary approach to depression treatment is very real, too.

Do you find yourself grappling with treatment-resistant depression, having exhausted various antidepressants without success? Discover renewed hope through Spravato®, a breakthrough nasal spray offered by American Behavioral Clinics. Many patients have reported significant improvements in symptoms within just four weeks, and the treatment is covered by most major insurance providers.

Don’t endure persistent depression any longer—take action today by calling or booking online to embark on your journey towards a brighter, more fulfilling life.

Spravato®, a nasal spray containing esketamine, is utilized in tandem with oral antidepressants to address specific cases of major depressive disorder (MDD). FDA-approved for adults with depression who have not responded to conventional treatments, or those struggling with depression accompanied by thoughts of self-harm or suicide, Spravato® represents a cutting-edge solution.

Ensuring patient safety remains our paramount concern. While Spravato® stands as a viable treatment for severe depression, individuals treated at ABC must maintain community safety. Those experiencing active suicidal thoughts or feeling unsafe should seek immediate assistance at a crisis center or hospital.

You may be an eligible candidate for Spravato® treatment if you meet the following criteria:

• Diagnosed with major depressive disorder or treatment-resistant depression.
• Unresponsive to other forms of treatment like psychotherapy, antidepressant medications, or lifestyle changes.
• Experiencing major depressive disorder with thoughts of self-harm or suicide while maintaining personal safety in the community (hospitalization may be required depending on the severity).
• Aged 18 years or older.
• Willing to adhere to safety measures recommended by your provider.

If you meet these criteria and believe Spravato® could be a suitable option, consult your provider for a comprehensive evaluation of your symptoms and information on how Spravato® or alternative treatments can effectively manage your depression.

Esketamine is a form of the combination medicine ketamine, widely used in medicine for anesthesia and occasionally as a recreational drug. Notably, the doses of esketamine employed in depression treatment are substantially lower, and Spravato® administration occurs in a controlled environment. Esketamine’s increased potency allows for lower doses, minimizing side effects. Although Spravato® may induce dissociation, the dosage is insufficient to produce intoxication or anesthesia.

Spravato® is FDA-approved for adults with treatment-resistant depression or major depressive disorder accompanied by thoughts of self-harm or suicide. However, it’s crucial to consult your healthcare provider to determine if Spravato® is the right option for you.

Functioning as an NMDA receptor antagonist, Spravato® attaches to and inhibits NMDA receptors in the brain. This action elevates glutamate levels, initiating downstream processes that enhance the growth and connectivity of neurons.

In contrast to many traditional antidepressants, Spravato® does not operate by inhibiting the reuptake of serotonin, norepinephrine, or dopamine. The exact mechanism behind Spravato®’s antidepressant effects remains under investigation.